Key references: Step 1 as-required therapy for asthma in adults and adolescents

  • Dusser D, Montani D, Chanez P, de Blic J, Delacourt C, Deschildre A, et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy 2007;62(6):591–604. https://www.ncbi.nlm.nih.gov/pubmed/17508962
  • O’Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, et al. Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. N Engl J Med 2018;378(20):1865–76. https://www.ncbi.nlm.nih.gov/pubmed/29768149
  • Reddel HK, Ampon RD, Sawyer SM, Peters MJ. Risks associated with managing asthma without a preventer: urgent healthcare, poor asthma control and over-the-counter reliever use in a cross-sectional population survey. BMJ Open 2017;7(9):e016688. https://www.ncbi.nlm.nih.gov/pubmed/28947448
  • Stanford RH, Shah MB, D’Souza AO, Dhamane AD, Schatz M. Short-acting beta-agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol 2012;109(6):403–7. https://www.ncbi.nlm.nih.gov/pubmed/23176877
  • Suissa S, Ernst P, Boivin JF, Horwitz RI, Habbick B, Cockroft D, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 1994;149(3 Pt 1):604–10. https://www.ncbi.nlm.nih.gov/pubmed/8118625